(84) demonstrated that immunotherapy with CTLA-4, PD-1, or PD-L1 inhibitors provided a significantly shorter median OS in patients with mucosal melanoma than in those with cutaneous melanoma (18 vs. 45 months; P = 0.003). This evidence concerns the gene CTLA4 and cutaneous melanoma.